tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BIIB Stock Latest News

UK’s MHRA approves Biogen’s Zurzuvae for postnatal depression
The FlyUK’s MHRA approves Biogen’s Zurzuvae for postnatal depression
1d ago
BIIB
Biogen, Stoke Therapeutics present data from studies of zorevunersen
PremiumThe Fly
Biogen, Stoke Therapeutics present data from studies of zorevunersen
4d ago
BIIB
STOK
Eisai and Biogen launch Leqembi in Austria, Germany
PremiumThe Fly
Eisai and Biogen launch Leqembi in Austria, Germany
4d ago
BIIB
Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights
PremiumCompany Announcements
Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights
6d ago
BIIB
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
PremiumCompany Announcements
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
6d ago
BIIB
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?
PremiumCompany AnnouncementsBiogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?
6d ago
BIIB
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection
Premium
Company Announcements
Biogen’s Promising Phase 3 Trial: Felzartamab for Kidney Transplant Rejection
7d ago
BIIB
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
Premium
Company Announcements
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
8d ago
BIIB
Biogen’s Innovative Litifilimab Study: A Potential Game-Changer in Drug Delivery
PremiumCompany Announcements
Biogen’s Innovative Litifilimab Study: A Potential Game-Changer in Drug Delivery
8d ago
BIIB
Biogen’s New Clinical Trial: A Potential Game-Changer for Kidney Transplant Patients
PremiumCompany Announcements
Biogen’s New Clinical Trial: A Potential Game-Changer for Kidney Transplant Patients
13d ago
BIIB
Biogen’s Omaveloxolone Study: A New Hope for Young FA Patients
PremiumCompany Announcements
Biogen’s Omaveloxolone Study: A New Hope for Young FA Patients
13d ago
BIIB
Biogen’s Litifilimab Study: A Long-Term Look at Lupus Treatment
PremiumCompany Announcements
Biogen’s Litifilimab Study: A Long-Term Look at Lupus Treatment
13d ago
BIIB
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy
PremiumCompany AnnouncementsBiogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy
14d ago
BIIB
Biogen price target raised to $118 from $115 at Piper Sandler
Premium
The Fly
Biogen price target raised to $118 from $115 at Piper Sandler
14d ago
BIIB
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments
Premium
Company Announcements
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Treatments
15d ago
BIIB
Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment?
PremiumCompany Announcements
Biogen’s PREVAIL Study: A New Hope for IgA Nephropathy Treatment?
16d ago
BIIB
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment
PremiumCompany Announcements
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment
17d ago
BIIB
Stoke Therapeutics, Biogen announce first patient dosed in EMPEROR study
PremiumThe Fly
Stoke Therapeutics, Biogen announce first patient dosed in EMPEROR study
17d ago
BIIB
STOK
Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study
PremiumThe Fly
Biogen, Stoke announce first patient dosed in Phase 3 EMPEROR study
17d ago
BIIB
STOK
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment
PremiumCompany AnnouncementsBiogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment
20d ago
BIIB
Biogen’s PIERRE-PK Study: A New Approach to Nusinersen Delivery in SMA
Premium
Company Announcements
Biogen’s PIERRE-PK Study: A New Approach to Nusinersen Delivery in SMA
20d ago
BIIB
Biogen’s Innovative Approach to SMA Treatment: ThecaFlex DRx™ System Study Update
Premium
Company Announcements
Biogen’s Innovative Approach to SMA Treatment: ThecaFlex DRx™ System Study Update
20d ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >